Medimaps recently attended the 2019 28th Annual AACE (American Association of Clinical Endocrinologists) Scientific & Clinical Congress held in Los Angeles from April 24th-28th. Over 2000 attendees from 35+ countries were present including over 90 national and international speakers from leading hospitals and practices from around the world.
Medimaps generated quite a bit of interest, giving us the opportunity to network and discuss TBS iNsight with doctors and practitioners from numerous countries.
TBS was highlighted in several presentations and scientific posters demonstrating its clinical value in patients with secondary osteoporosis. A few of them are listed below.
One of the oral presentations overviewed by medpagetoday.com showed potential additional clinical value of TBS in managing patients on Hemodialysis. The presentation was given by Roxana Dusceac, MD, PhD candidate, of Carol Davila University of Medicine and Pharmacy in Bucharest, Romania.
Dr. Steven Petak of Houston Methodist Academic Medicine Associates gave a presentation on the clinical value of TBS in the everyday practice of endocrinology with emphasis on the treatment of secondary osteoporosis.
Additionally, an abstract presented in the Poster Gallery by Jorge Valladares, MD – Fellow, ABC Medical Center, Joaquin G. Joya-Galeana, MD – Endocrinology, Endo PLus, and Maria Guillen-Placencia, MD – Resident, Centro Médico ABC, all from Mexico City, Mexico, demonstrated potential clinical value for patients with cardiovascular risk. This study finds an association between deterioration of microarchitecture with ASCVD risk and suggest that high cardiovascular risk males should be evaluated for fracture risk with TBS.